Although external collaboration capability influences the development of personalized medicine, key transactions in the pharmaceutical industry have not been addressed. To explore specific trends in interorganizational transactions and key players, we longitudinally surveyed strategic transactions, comparing them with other advanced medical developments, such as antibody therapy, as controls. We found that the financing deals of start-ups have surged over the past decade, accelerating intellectual property (IP) creation. Our correlation and regression analyses identified determinants of financing deals among alliance deals, acquisition deals, patents, research and development (R&D) licenses, market licenses, and scientific papers. They showed that patents positively correlated with transactions, and that the number of R&D licenses significantly predicted financing deals. This indicates, for the first time, that start-ups and investors lead progress in personalized medicine.

尽管外部协作能力会影响个性化医学的发展，但制药行业的关键交易尚未得到解决。为了探索组织间交易和关键参与者的特定趋势，我们对战略交易进行了纵向调查，并将其与其他先进的医学进展（例如抗体疗法）作为对照进行比较。我们发现，在过去十年中，初创企业的融资交易激增，加速了知识产权（IP）的创建。我们的相关性和回归分析确定了联盟交易，收购交易，专利，研究与开发（R＆D）许可，市场许可和科学论文中融资交易的决定因素。他们表明专利与交易成正相关，R＆D许可证显着预测了融资交易。这首次表明，初创企业和投资者引领着个性化医学的发展。